Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Consolidated Net Income (2022 - 2026)

Phathom Pharmaceuticals has reported Consolidated Net Income over the past 5 years, most recently at -$29.5 million for Q1 2026.

  • Quarterly Consolidated Net Income rose 68.67% to -$29.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$156.3 million through Mar 2026, up 54.8% year-over-year, with the annual reading at -$221.1 million for FY2025, 33.88% up from the prior year.
  • Consolidated Net Income was -$29.5 million for Q1 2026 at Phathom Pharmaceuticals, down from -$21.1 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at -$21.1 million in Q4 2025 and troughed at -$94.3 million in Q1 2025.
  • The 5-year median for Consolidated Net Income is -$51.1 million (2022), against an average of -$57.9 million.
  • Year-over-year, Consolidated Net Income tumbled 123.2% in 2024 and then surged 71.62% in 2025.
  • A 5-year view of Consolidated Net Income shows it stood at -$55.0 million in 2022, then crashed by 44.76% to -$79.6 million in 2023, then grew by 6.36% to -$74.5 million in 2024, then surged by 71.62% to -$21.1 million in 2025, then tumbled by 39.71% to -$29.5 million in 2026.
  • Per Business Quant, the three most recent readings for PHAT's Consolidated Net Income are -$29.5 million (Q1 2026), -$21.1 million (Q4 2025), and -$30.0 million (Q3 2025).